AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02355509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months
Study NCT02355509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills are given instead of acarbose in this group
Study NCT01839643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 3.0 g
Description: 3.0 g in Vaginal Ring
Study NCT04871373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: A periodontist was trained and evaluated by two expert psychologists in MI, who also supervised the interviewer to ensure that the intervention was properly applied. The periodontist conducted sessions of motivational interviewing monthly to the participants of the experimental group.
Study NCT04871373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instructions
Description: A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
Study NCT04871373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Hygiene Instructions
Description: A periodontist delivered OHI to all the participants of both studied groups. Also, every single patient received a G.U.M. kit with special orthodontic hygiene tools.
Study NCT02093143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
Study NCT00048854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
Study NCT00069953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients >70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
Study NCT00069953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
Study NCT00048854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
Study NCT03194776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LLG783
Description: LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Study NCT03194776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
Study NCT02492061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demand creation for couples' HCT
Description: The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
Study NCT00290082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loxapine, midazolam
Description: agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
Study NCT00290082 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: was evaluated in patients sedated, alcohol level, blood sugar
Study NCT00290082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient monitoring
Description: Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
Study NCT00290082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxapine
Description: Loxapine 1 mL / 10 kg
Study NCT00290082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 1 mL / 10 Kg
Study NCT00069953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
Study NCT02851043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneuRIP (breathing with resistance)
Description: subjects are given a resistance element to breath through
Study NCT02851043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respitrace system (Carefusion) (breathing without resistance)
Description: subjects are asked to breath normally
Study NCT01648218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral protamine hagedorn (NPH) insulin
Study NCT01903239 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Low-Risk BCC Excisional Margins
Description: After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
Study NCT00069953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
Study NCT01648218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular human insulin or Insulin Aspart
Study NCT01648218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study NCT00069953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
Study NCT06264193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: The athletes were living in hypoxic rooms, and training was carried out on lowlands.
Study NCT05900453 — intervention group
Intervention type: OTHER
Intervention: Clinical decision support (CDS) tool
Description: The web-based clinical decision support (CDS) tool uses patient information (e.g., age, sex, BMI, perioperative status) to create personalized predictions of recovery following knee replacement. The CDS tool predicts range of motion, physical function, and pain recovery. Clinicians can use these predictions to (1) inform patients of their expected prognosis, (2) monitor patients' recovery against their predicted recovery, and (3) tailor treatments according to individual patients' needs.~Clinicians were provided with basic training for how to use the CDS tool, and were given examples of how to integrate it into clinical care. However, the CDS tool did not dictate any treatment decisions; clinicians were free to use the CDS tool at their discretion to inform decision making.
Study NCT03676036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107E
Study NCT03676036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01632358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311 capsules
Study NCT01632358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01442974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus nab-paclitaxel
Description: Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
Study NCT00591357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loperamide
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Study NCT00591357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
Study NCT00530179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Blood Stem Transplantation
Description: 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
Study NCT00530179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: 6 - 21 DAY Cycles of R-CHOP
Study NCT02846662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONEMO
Description: The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
Study NCT02887950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
Study NCT02887950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Equikilon-3 months
Description: The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
Study NCT02887950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Equikilon-6 months
Description: The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
Study NCT00971516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: dental implant placement
Study NCT00971516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants surgery
Description: dental implant surgery
Study NCT00253903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration
Study NCT00253903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT01429714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individually tailored duration of elastic compression therapy
Description: Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
Study NCT01429714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastic compression therapy with a standard duration of 24 months
Description: Elastic compression therapy with a standard duration of 24 months
Study NCT01055106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen A
Study NCT01055106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen B
Study NCT01055106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW05
Description: vaginal gel once daily regimen C
Study NCT01055106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: vaginal gel 0.75% once daily for 5 days
Study NCT03748537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
Study NCT01355783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E7777
Description: Treatment in both arms is for 6 cycles at 21 days/cycle.
Study NCT03285009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training intervention
Description: Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school.
Study NCT04356105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minimal stimulation protocol
Description: Letrozole, Recombinant FSH, GnRH antagonist
Study NCT04356105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microflare protocol
Description: OCP, GnRH agonist, Recombinant FSH
Study NCT04356105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI cycle
Description: Involving ovum pickup and embryo transfer
Study NCT01674543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
Study NCT01674543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
Study NCT01674543 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
Study NCT02288975 — intervention group
Intervention type: DEVICE
Intervention: CytoSorb 300ml device (3804606CE01)
Study NCT01992198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefoperazone + metronidazole
Description: 1.Clinical parameters (2 of 3):~1)temperature\<37.8℃ or 2)HR \<100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC \<12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed \<30% compared to that of 72h
Study NCT01992198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral care by chlorhexidine gluconate
Description: oral care by 0.2% chlorhexidine gluconate twice daily
Study NCT01992198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral care by chlorhexidine gluconate
Description: oral care by 0.2% chlorhexidine gluconate twice daily
Study NCT03174743 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Convential Ventilation 1
Description: High tidal volume, moderate inspired oygen fraction (FiO2).
Study NCT03174743 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Convential Ventilation 2
Description: High tidal volume, high inspired oygen fraction (FiO2).
Study NCT03174743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective Ventilation 1
Description: Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
Study NCT03174743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective Ventilation 2
Description: Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
Study NCT02353078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Sucralfate slurry 1 gram four times daily for four weeks
Study NCT02353078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraluminal Impedance
Description: During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
Study NCT02353078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraluminal Impedance
Description: The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
Study NCT05090540 — intervention group
Intervention type: DEVICE
Intervention: Trancatheter Edge to Edge Repair
Description: TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
Study NCT05090540 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral Valve Replacement
Description: Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
Study NCT05090540 — intervention group
Intervention type: PROCEDURE
Intervention: Restrictive Mitral Annuloplastie
Description: Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
Study NCT05090540 — intervention group
Intervention type: PROCEDURE
Intervention: Restrictive Mitral Annuloplastie/Subvalvular Repair
Description: RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
Study NCT01992198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enteral nutrition